

— OFFICIAL —

best of  Greece

SABCS®

ATHENS, GREECE / JANUARY 13th, 2024 / Divani Caravel Hotel

SCIENTIFIC PROGRAM



SABCS® is the owner of the Trademark for all content related to the SABCS® Symposium Material and any derivatives thereof.

Organized by



Under the Auspices of



AN INITIATIVE OF
ENCORE
MEDICAL EDUCATION

SPONSORS



SPONSORS



Oncology



Pierre Fabre
FARMAKA S.A.



Advancing Life Sciences - Innovating Health Care[™]



From transformative medicines that take on the toughest challenges, to biosimilar and supportive care outcome-enabling solutions we're

ADVANCING ALL ANGLES OF CARE

AMGEN®

Oncology

GRC-NP-1123-80011

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

Αναφέρετε κάθε ύποπτη ανεπιθύμητη ενέργεια σύμφωνα με το εθνικό σύστημα αναφοράς στο Τμήμα Ανεπιθύμητων Ενέργειων του Εθνικού Οργανισμού Φαρμάκων (ΕΟΦ) Τηλ: 2132040300, Fax: 2106446565, με τη χρήση της Κίτρινης Κάρτας Διασφάλισης και στην ιστοσελίδα του ΕΟΦ www.eof.gr για έντυπη ή ηλεκτρονική υποβολή ή εναλλακτικά στην AMGEN Ελλάς Φαρμακευτικά Ε.Π.Ε. Τηλ: +30 2103447000.

AMGEN HELLAS ΕΠΕ
Αγ. Κωνσταντίνου 59-61
Green Plaza, κτίριο Γ, 15 124 Μαρούσι
Τηλ: 210 3447000 - Fax: 210 3447050
Email: info@amgen.gr, www.amgen.gr

WELCOME LETTER

Dear friends and colleagues,

We welcome you to the ninth edition of the Best of SABCS-Greece, an aggregation of the most important research in breast cancer presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).

The SABCS is the premier conference for basic, translational and clinical breast cancer research professionals. It is well known for the presentation and discussion of the latest breast cancer data from all over the world.

The Best of SABCS program has been organized specifically for clinicians to experience a condensed version of the most impactful highlights of science and education from the SABCS.

The program review and critically assess practice-changing results of emerging breast cancer research, propose best practices for implementing diagnostic and therapeutic strategies, and close knowledge and clinical practice gaps in the management of patients with breast cancer.

Here are some of the highlights of this year's Best of SABCS-Greece:

- Important new data on breast and lymph node radiation therapy.
- Updates on important studies in early disease.
- The evolving landscape of treatment after CDK4/6 inhibitors.
- Results from promising newer agents in metastatic disease.
- Reassuring data on the safety of assisted reproduction and pregnancy after breast cancer.

We look forward to welcoming you in Athens and wish you a fruitful BoSABCS experience.

Emmanouil Saloustios
ASS. PROFESSOR OF ONCOLOGY

Faculty of Medicine, School of Health Sciences,
University of Thessaly, Larissa, Greece

KEYTRUDA[®]

(pembrolizumab) for Infusion 100mg

Για την πλήρη περίληψη των χαρακτηριστικών του προϊόντος, παρακαλούμε να απευθύνεστε στην MSD ΑΦΒΕΕ, Αγίου Δημητρίου 63, 174 56, Άλιμος. Τηλ.: 210 9897 300, Αρ. ΓΕΜΗ 121808101000

KEYTRUDA C/S.SOL.IN 25MG/ML BTx1 VIALx4ML : 2.593,93 € (Χ.Τ) 2.818,31 € (Λ.Τ) 2.332,24 € (Ν.Τ.)



Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και **Αναφέρετε ΟΛΕΣ** τις ανεπιθύμητες ενέργειες για **ΟΛΑ** τα φάρμακα Συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»

GR-KEY-00758-16/10/2023

PROGRAM

08.30-09.00 **Welcome**

09:00- 10:30 **Session 1: Basic and Translational Science and Risk Assessment**

Chairs: S. Agelaki, Ch. Kalofonos

09.00-09.30 Basic and Translational Science

N. Prekete

09.30-10.00 Risk Assessment

F. Zagouri

Discussion

F. Fostira, S. Lanitis, E. Maragouli, D. Mauri, C. Panopoulos

10:30-12:00 **Session 2: Locoregional disease management**

Chairs: V. Kouloulias, V. Venizelos

10.30-11.15 Presenter: T. Mamounas

Discussion

I. Askoxyllakis, E. de Bree, M. Kontos, G. Kyrgias, K. Tepetes, C. Tsiou, G. Xepapadakis

12:00-12:30 **Break**

12:30-14:00 **Session 3: Early disease**

Chairs: A. Koutras, C. Papadimitriou

12.30-13.00 HR +

D. Tryfonopoulos

13.00-13.30 HER2+ and TNBC

E. Kontopodis

Discussion

N. Alevizopoulos, V. Barbounis, G. Lambrodinou, A. Koumariou

14:00-15:00 **Lunch Break**

15:00-16:45 **Session 4: Advanced disease**

Chairs: V. Georgoulas, K. Papazisis

15.00-15.45 Presenter: V. Kaklamani

15.45-16.15 Novel Therapeutics

Y. Marcou

Discussion

A. Kotsakis, E. Lianos, E. Timotheadou, K. Tsapakidis

16.45-18.00 **Session 5: Survivorship**

Chairs: N. Androulakis, E. Lalla

16.45-17.05 Survivorship and Pregnancy

A. Zavos

17.05-17.25 Treatment-related toxicities

A. Kokkalis

Discussion

A. Ardavanis, I. Drositis, M. Kanara, P. Michalopoulou, D. Papageorgiou

Arvekap® 3,75mg
triptorelin

IPSEN
Innovation for patient care



Arvekap® ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ
triptorelin

ΕΝΔΕΙΚΝΥΤΑΙ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΜΑΣΤΟΥ

Ως επικουρική θεραπεία σε συνδυασμό με ταμοξιφαίνη ή με αναστολέα αρωματάσης, σε ενδοκρινικά ανταποκρινόμενο καρκίνο του μαστού αρχικού σταδίου, σε γυναίκες με υψηλό κίνδυνο υποτροπής, οι οποίες είναι επιβεβαιωμένα προεμμηναυσιακές, μετά την ολοκλήρωση της χημειοθεραπείας¹.

1. Arvekap® 3,75mg, Περίληψη Χαρακτηριστικών Προϊόντος
Συνταγογραφικές πληροφορίες του προϊόντος σε επόμενη
σελίδα του εντύπου. (σελ. 18-19)

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

14 ARV 11,25/3,75/22,5-B/ΣΕΠ 2022

IPSEN
Innovation for patient care

IPSEN MON. ΕΠΕ

ΑΓΙΟΥ ΔΗΜΗΤΡΙΟΥ 63, 174 56 ΑΛΙΜΟΣ, ΑΘΗΝΑ
ΤΗΛ.: 210 9843324, 210 9858930, FAX: 210 9887911

E-mail: ipsenepe@ipsen.com, http://www.ipsen.gr

Τηλέφωνα Φαρμακοεπαγρύπνησης: 210 9843324, 210 9858930

OFFICIAL
best of Greece
SABCS®

ATHENS, GREECE / JANUARY 13th, 2024 / Divani Caravel Hotel
SABCS® is the owner of the Trademark for all content related to the SABCS® Symposium Material and any derivatives thereof.



SABCS 2023 High Impact Science

- (GS03-04) Novel Mechanisms of CDH1 Inactivation in Breast Invasive Lobular Carcinoma Unveiled by the Integration of Artificial Intelligence and Genomics
- (GS03-06) Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
- (GS03-07) Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer.
- (GS03-09) Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
- (GS02-04) Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival
- (PS10-01) Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2
- (PS10-02) Association between Germline Mutation Status and Overall Survival among Women with Breast Cancer in Population-based Studies in the United States
- (PS10-03) Impact of Baseline Oestradiol and Testosterone on the Preventive Effect of Anastrozole
- (PS10-08) Validation of a clinical image-based AI-risk model for individualized breast cancer screening in a multi-national setting
- (GS02-05) Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials
- (GS02-06) Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.
- (GS02-07) Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
- (GS02-08) Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
- (PS03-06) Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: saving costs and time (the CONFIDENT-B trial)
- (PS10-08) Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112
- (PS18-01) Stage Advancement and The Rate of Growth Associated with Preoperative Delay in Patients Having Breast Cancer
- (GS01-01) Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL
- (GS01-02) Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2- breast cancer: KEYNOTE-756
- (GS03-01) Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112



▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει τον γρήγορο προσδιορισμό νέων ασφαλείας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιοδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες στον Εθνικό Οργανισμό Φαρμάκων. Μεσογείων 284 GR-15562 Χολαργός, Αθήνα, Τηλ: +30 21 32040380/337, Φαξ: +30 21 06549585, Ιστότοπος: <http://www.eof.gr>. Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία AstraZeneca A.E.

Το Enhertu θα πρέπει να συνταγογραφείται από ιατρό και να χορηγείται υπό την επίβλεψη επαγγελματία υγείας, έμπειρου στην χορήγηση αντικαρκινικών φαρμακευτικών προϊόντων.



AstraZeneca A.E., Αγησιόλου 6-8, 15123 Μαρούσι, Αθήνα
Τηλ.: 210 6871500, Fax: 210 6859195
Αρ. Γ.Ε.ΜΗ. 000638901000
www.astrazeneca.gr

Κάτοχος Άδειας Κυκλοφορίας: Daiichi Sankyo Europe GmbH

Τοπικός Αντιπρόσωπος: AstraZeneca AE

Τιμές • Χ.Τ.: 1636,66€ • Ν.Τ.: 1471,54€ • Α.Τ.: 1799,91€

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

ENH/00020/1/0523

- (GS03-03) Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial
- (PS13-09) Molecular and immunological landscape of sex-based differences in breast cancer: a distinct disease in men
- (PS14-06) Real-world analysis of adverse events in patients with triple negative breast cancer receiving therapy per KEYNOTE-522
- (GS02-01) Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01.
- (GS02-10) Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
- (GS01-10) HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
- (PS11-01) Brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients
- (PS11-05) Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study
Novel Therapies
- (PS15-03) Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: phase 1b cohort
- (PS15-07) Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase 1c Study
- (PS15-08) Final Overall Survival (OS) analysis of the SAKK 21/12 trial. CR1447 in HR+/HER2- metastatic breast cancer and androgen receptor positive triple negative breast cancer.
- (PS17-09) An FGFR1/2 degrader overcomes antiestrogen resistance in ER+/FGFR1-amplified breast cancer
- (GS02-11) Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
- (GS02-13) Pregnancy after breast cancer in young women with germline pathogenic variants: results from an international cohort study
- (PS02-05) Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer
- (PS13-01) Worse Prognosis for Breast Cancer in the Second and Third Trimesters and Shortly Postpartum: An Update of the Dutch Pregnancy-Associated Breast Cancer Cohort
- (PS13-02) Clinical Outcome and Patients' Characteristics of Breast Cancer Diagnosed During Pregnancy: A Retrospective Single Institutional Study
- (PS13-03) Safety of taxane chemotherapy for the treatment of breast cancer during pregnancy: an international cohort study
- (PS13-07) Systemic therapy in geriatric patients with triple negative breast cancer: a National Cancer Database analysis
- (PS14-01) Immune related adverse events in patients ≥65 years vs. < 65 years with breast cancer treated with immunotherapy
- (PS18-07) Trends in Guideline Concordant Care for Inflammatory Breast Cancer: An analysis of the National Cancer Database

OYAVAS®

bevacizumab



OYAVAS 367/1 06/2022

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφαλείας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιοσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών Προϊόντος



KAK: STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel, Germany



Προωθείται από την εταιρία:
21^ο χλμ Εθν. Οδού Αθηνών-Λαμίας,
145 68 Κρουσέρι, Αττικής, Ελλάδα
T: +30 210 8161802, F: +30 210 8161587

FACULTY

- Agelaki S.** Professor of Medical Oncology, Laboratory of Translational Oncology, University Hospital of Heraklion University, Crete
- Alevizopoulos N.** Medical Oncologist, Evaggelismos General Hospital, Athens
- Androulakis N.** Medical Oncologist, Head of the Medical Oncology Department, Venizeleio-Pananeio General Hospital, Heraklion, Crete
- Askoxyllakis I.** Breast Surgeon Oncologist, University Hospital of Heraklion, Crete
- Ardavanis A.** MD, PhD, Medical Oncologist, Head of 1st Department of Medical Oncology, Agios Savvas Anticancer Hospital, Athens
- Barbounis V.** MD, PhD, Medical Oncologist IASO Hospital, Athens
- de Bree E.** Professor of General Surgery - Surgical Oncology, Medical School of Crete, Head, Department of Surgical Oncology, University Hospital of Heraklion, Crete
- Drositis I.** MD, PhD, MSc, Consultant Medical Oncologist, Venizeleio - Pananeio General Hospital, Heraklion, Crete
- Fostira F.** PhD, Clinical Laboratory Geneticist, ErCLG, Faculty Researcher, Human Molecular Genetics Laboratory, NCSR Demokritos, Athens
- Georgoulas V.** Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Heraklion, Crete
- Kaklamanis V.** MD, DSc, Professor of Medicine, Ruth McLean Bowman Bowers, Chair in Breast Cancer Research and Treatment, A.B. Alexander Distinguished Chair in Oncology, Leader, Breast Oncology Program, UT Health San Antonio, MD Anderson Cancer Center, USA
- Kalofonos C.** MD, PhD, Emeritus Professor of Medical Oncology, Head Division of Oncology, Olympion Hospital, Patras
- Kanara M.** FEBS, MD, MSc, PhD, Consultant Breast Surgeon, General Hospital of Trikala, Thessaly
- Kokkalis A.** Medical Oncologist, MSc, PhD Candidate, University Hospital of Larissa
- Kontopodis E.** MD, Medical Oncologist, Attending Physician, Venizeleion General Hospital, Heraklion, Crete
- Kontos M.** Professor in Breast and General Surgery, National and Kapodistrian University of Athens, 1st Department of Surgery, Laiko University Hospital, Athens
- Kotsakis A.** MD, PhD, Professor of Medical Oncology, School of Medicine, University of Thessaly, Director of the Department of Medical Oncology, General University Hospital of Larissa
- Kouloulis V.** MD, PhD, Professor of Radiation Oncology, School of Medicine, National and Kapodistrian University of Athens, Head of Radiotherapy Unit, 2nd Department of Radiology, Attikon University Hospital, Athens
- Koumarianou A.** MD, PhD, Consultant Medical Oncologist, 4th Department of Internal Medicine, Hematology-Oncology Unit, Attikon University Hospital, Athens
- Koutras A.** Professor of Medical Oncology, Medical School, University of Patras, Head of the Division of Oncology, Department of Medicine, University Hospital of Patras
- Kyrgias G.** Professor of Radiation Oncology, Head Radiation Oncology / Radiotherapy Department, University Hospital of Larissa
- Lalla E.** Medical Oncologist, Theageoneo Cancer Hospital, Thessaloniki

Letrafem®

Δισκία λετροζόλης 2.5 mg

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΑΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



ARITI A.E. ΑΘΗΝΑ: Λεωφ. Τατοίου 52,
13677 Αχαρνές
Τηλ.: 210 8002650 - Fax: 210 6207503
www.ariti.gr - info@ariti.gr

ariti®
Σημά στον άνθρωπο



AMERICAN
RADIOLOGICAL
SOCIETY

OFFICIAL
best of Greece
SABCS®

ATHENS, GREECE / JANUARY 13th, 2024 / Divani Caravel Hotel
SABCS® is the owner of the Trademark for all content related to the SABCS® Symposium Material and any derivatives thereof.



Lambrodimitou G. Medical Oncologist, Oncology Unit, General Hospital, Larissa

Lanitis S. MD, PhD, Head, 2nd Surgical Department and Unit of Surgical Oncology, Korgialenio-Benakio National, Red Cross Athens General Hospital, Athens

Lianos E. MD, Medical Oncologist, sr Consultant MedOnc Department METAXA Memorial Cancer Center Hospital, Piraeus

Mamounas E. MD, MPH, FACS, Medical Director, Comprehensive Breast Program, Orlando Heath Cancer Institute, Orlando, FL, USA / Professor of Surgery, University of Central Florida College of Medicine, Clinical Professor of Clinical Sciences, Florida State University College of Medicine, USA

Maragkouli E. Medical Oncologist, MD General Hospital of Larissa and General Hospital of Trikala, Thessaly

Markou Y. MRCP, FRCP, Consultant Medical Oncologist, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

Mauri D. Assistant Professor of Medical Oncology, School of Medicine, University of Ioannina

Michalopoulou P. President of the Board of Directors, Hellenic Association of Women with Breast Cancer "Alma Zois", Athens

Panopoulos C. MD, PhD, Medical Oncologist, Head of Oncology Department, Euroclinic of Athens

Papadimitriou C. MD, PhD, Professor of Therapeutics - Oncology Head, Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens

Papageorgiou D. Assistant Professor University of Peloponnese, Head Nurse Oncology Unit Euroclinic Athens, President of Hellenic Oncology Nursing Society

Papazisis K. Consultant Medical Oncologist, Head Oncology Department, Euromedica General Clinic, Thessaloniki

Prekete N. PhD, Scientific Associate, Molecular Diagnostics Unit, 1st Department of Pathology, Medical School, University of Athens

Tepetes K. MD, ScD, FACS, EBSQ Surgical Oncology, Professor of General Surgery, Head of the Surgical Sector, Faculty of Medicine School of Health Sciences, University of Thessaly

Timotheadou E. Associate Professor in Medicine and Oncology, Head, Department of Medical Oncology, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki

Tryfonopoulos D. MD, MSc, PhD, Consultant Medical Oncologist, Saint Savvas Anticancer Hospital, Athens

Tsapakidis K. Medical Oncologist, University Hospital of Larissa

Tsionou C. MD, PhD, Gynecologist Breast Surgeon, Head of 1st Breast Clinic, MITERA Hospital, Athens

Venizelos V. MD, Oncoplastic Breast Surgeon, Director of Breast Unit, Metropolitan Hospital, Piraeus

Xepapadakis G. Breast Surgeon, Director, 2nd Breast Clinic, Iaso Hospital, Founder of the E.M.E.I.S. (Scientific Mammological Society Iasi Support)

Zavos A. MD, PhD, Gynecologist Breast Surgeon, Representative of Greece in UEMS for Breast cancer, Lecturer in Ob/Gyn Department University of Thessaly, Larissa, Greece Gynecologist, Breast surgeon, University of Larissa

Zagouri F. Professor of Medical Oncology, National and Kapodistrian University of Athens, Alexandra Hospital, Athens

Breast Cancer – The Next Stage

A molecular diagnostic test for quantitative determination of the **4 key biomarkers** used in the subtyping of breast cancer



Innovation for your breast cancer diagnostics

- High-performance** Precise quantitative results for mRNA expression of HER2, ER, PR and Ki-67 Outperforms IHC by accurate Ki-67 determination
Accurate and reliable test to stratify breast cancer into surrogate subtypes acc. to St Gallen
- Reproducible** Highly reproducible results with extremely low inter-/intra-laboratory variation
- Validated** Clinical value has been validated in numerous performance evaluation studies
- Prognostic** Extended information on patient's prognosis
- Predictive** Accurate subtyping supports treatment decisions
- Optimized** Reliable method for any pathology laboratory
- Easy-to-use** Easy-to-use test which allows results within 6 hours

GENERAL INFORMATION

Organized by



Under the Auspices of



Symposium Venue

Divani Caravel Hotel
Vassileos Alexandrou Ave., 16121, Athens, GREECE
Tel.: +30 210 72.07.000
Fax: +30 210 72.36.683
E-mail: info@divanicaravel.gr

Date

13th, January, 2024

Live streaming and on demand viewing will not be available to this event.

Attendee Certificate of Participation

Attendees to Official Best of SABCS programs are expected to register at www.bestofsabcs.com to receive the official Certificate of Participation.

Secretariat



Scientific | Cultural Events & Publications

T +30 210 7240039 E info@scep.gr

www.scep.gr



